Table 4.
IMN and tumour biology
| IMN and Correlation with Tumour Grade | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiable IMN on Baseline CT (n = 77) | No Identifiable IMN on Baseline CT (n = 105) | ||||||||||
| Grade 1 | 0 | 0% | Grade 1 | 01 | 0.01% | ||||||
| Grade 2 | 6 | 7.80% | Grade 2 | 13 | 12.38% | ||||||
| Grade 3 | 71 | 92.20% | Grade 3 | 91 | 87.61% | ||||||
| Identifiable IMN with subsequent Metastases (n = 21) | No Identifiable IMN with subsequent Metastases (n = 15) | ||||||||||
| Grade 1 | 0 | 0% | Grade 1 | 0 | 0% | ||||||
| Grade 2 | 2 | 9.52% | Grade 2 | 0 | 0% | ||||||
| Grade 3 | 19 | 90.48% | Grade 3 | 15 | 100% | ||||||
| IMN and Correlation with Hormonal Receptor Status | |||||||||||
| Identifiable IMN on Baseline CT (n = 77) | No Identifiable IMN on Baseline CT (n = 105) | ||||||||||
| ER | PR | Her2/Neu | ER | PR | Her2/Neu | ||||||
| + | + | + | 10 | 12.99% | + | + | + | 10 | 9.52% | ||
| + | + | - | 19 | 24.66% | + | + | - | 35 | 33.33% | ||
| + | - | - | 9 | 11.69% | + | - | - | 8 | 7.62% | ||
| - | - | + | 13 | 16.88% | - | - | + | 15 | 14.29% | ||
| - | + | + | 0 | 0% | - | + | + | 1 | 0.10% | ||
| + | - | + | 3 | 3.90% | + | - | + | 3 | 2.86% | ||
| - | + | - | 0 | 0% | - | + | - | 0 | 0% | ||
| - | - | - | 23 | 29.88% | - | - | - | 33 | 32.28% | ||
| Identifiable IMN with subsequent Metastases (n = 21) | No Identifiable IMN with subsequent Metastases (n = 15) | ||||||||||
| ER | PR | Her2/Neu | ER | PR | Her2/Neu | ||||||
| + | + | + | 1 | 4.76% | + | + | + | 2 | 13.34% | ||
| + | + | - | 6 | 28.57% | + | + | - | 5 | 33.33% | ||
| + | - | - | 3 | 14.29% | + | - | - | 0 | 0% | ||
| - | - | + | 6 | 28.57% | - | - | + | 2 | 13.34% | ||
| - | + | + | 0 | 0% | - | + | + | 0 | 0% | ||
| + | - | + | 1 | 4.76% | + | - | + | 1 | 6.66% | ||
| - | + | - | 0 | 0% | - | + | - | 0 | 0% | ||
| - | - | - | 4 | 19.05% | - | - | - | 5 | 33.33% | ||